Vimta Labs Limited — Q2FY27 earnings call summary

Filed 04 November 2026 · Official transcript

Clinical research capacity limited by 180 beds; recovery expected as client base diversifies
Capex of INR80 crores planned for FY27, focused on analytical capabilities and self-service offerings
Q2 FY27 revenue grew 9.9% y-y to INR1,149 million; EBITDA up 10.5% y-y at INR408 million; PAT rose 3.5% y-y to INR206 million
Biologics services started revenue generation; expected to take 2-3 years to become substantial
Medium-term revenue growth target ~20-25% CAGR; confident in growth potential despite short-term pipeline lull
Preclinical business growing at ~30% CAGR over last 4 years; capacity expansion underway
EBITDA margin stable at ~35.5% in Q2; medium-term margin may decline 100-200 bps due to service mix shift
Electronics testing stable; capacity doubled; growth limited by nature of testing frequency